Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Ownership and Inventorship Ambiguity Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those…
In America, we are adept at electing clowns and charlatans, and then ignoring or not bothering to understand what they are saying or doing. I blame this on our addictions…
A Five-Part Series on AI Drug Discovery Valuation Challenges Introduction I have no idea. That was my brilliant, insightful, memorable, put this on a t-shirt answer to the question posed…
Introduction Part I of this article proposed a framework to help guide the discussion around repurposing, which we define very broadly. Now, in Part II, we extend the framework and…
Introduction Repurposing was at one time a very popular strategy, with some of the earliest blockbusters being novel formulations (usually new oral sustained release versions) of existing products. Generous regulatory pathways (like…
Experts predict that 2026 will bring mixed outcomes in the industry, with caution in investment approaches dominating trends. Concerns about safety versus innovation persist alongside debates on licensing versus M&A. Execution quality is emphasized as crucial, potentially overshadowing compelling scientific narratives. Uncertainty remains about strategic effectiveness in navigating upcoming challenges.
In every industry, revenue is driven by a simple equation: Revenue = (Price per Unit) × (Units Sold) For most sectors, both levers are available. A company can raise prices,…